Status:
RECRUITING
A Study on the Peripheral Blood in Patients With Acute Coronary Syndrome
Lead Sponsor:
Second Affiliated Hospital of Wenzhou Medical University
Collaborating Sponsors:
The Central Hospital of Lishui City
Conditions:
Acute Coronary Syndrome
Chronic Coronary Syndrome
Eligibility:
All Genders
18+ years
Brief Summary
The goal of this study is to conduct analyses the changes of cell growth factors, inflammatory factors, metabolites, plasma proteome, etc. in the blood of patients with ACS (acute coronary syndrome), ...
Eligibility Criteria
Inclusion
- For ACS group STEMI
- cTn\>99th ULN or CK-MB\>99th ULN
- ST-segment elevation with a convex upward morphology
- in conjunction with one or more of the following conditions: persistent ischemic chest pain; echocardiographic evidence of abnormal segmental ventricular wall motion; or abnormal coronary angiography findings.
- NSTEMI
- cTn\>99th ULN or CK-MB\>99th ULN
- accompanied by one or more of the following situations: persistent ischemic chest pain; new ST-segment depression or low and inverted T waves; echocardiography showing segmental ventricular wall motion abnormalities; abnormal coronary angiography.
- UA
- cTn normal
- ischemic chest pain with an electrocardiogram showing transient ST-segment depression or flattened and inverted T waves
- evidence of coronary artery stenosis (e.g., CTA demonstrating ≥ 50% stenosis) For CCS group
- Clinical Diagnosis Consistent with CCS Categories, meet any one of the following clinical scenarios: Stable Angina Pectoris, Ischemic Cardiomyopathy, Post-ACS Stable Phase, Long-Term CAD Management, Vasospastic or Microvascular Disease, Asymptomatic CAD
- Laboratory and Imaging Confirmation: Resting ECG without ST-segment elevation or dynamic changes (excluding ACS), cTn normal or stable (no acute myocardial injury), ≥50% luminal stenosis in ≥1 epicardial coronary artery For control group
- Patients without coronary artery stenosis, valvular heart disease, structural heart disease, or any other kind of cardiomyopathy
Exclusion
- Lactating or pregnant women
- Patients with malignant neoplasms
- Severe hepatic/renal dysfunction
- Severe hematological disorders
- Autoimmune diseases
Key Trial Info
Start Date :
March 11 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2025
Estimated Enrollment :
310 Patients enrolled
Trial Details
Trial ID
NCT06955143
Start Date
March 11 2025
End Date
December 1 2025
Last Update
July 25 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Lishui Central Hospital
Lishui, Zhejiang, China